No Data
No Data
Are Robust Financials Driving The Recent Rally In Yili Chuanning Biotechnology Co.,Ltd.'s (SZSE:301301) Stock?
Yili Chuanning BiotechnologyLtd's (SZSE:301301) stock is up by a considerable 77% over the past three months. Given the company's impressive performance, we decided to study its financial indicators
Twining Biotech (301301.SZ): No research on anti-aging drugs is currently being conducted
Gelonghui, May 17 丨 Chuan Ning Biology (301301.SZ) said on the investor interactive platform that the company is currently not conducting research on anti-aging drugs. In the field of biological fermentation, the company's main products include erythromycin thiocyanate intermediates, cephalosporin intermediates (7-ACA, 7-ADCA, D-7ACA), high-end cosmetic intermediates (6-APA, penicillin G potassium salt), crude ursodeoxycholic acid products, coenzyme Q10 mycelium, etc.; in the field of synthetic biology, the company focuses on health product ingredients, biopesticides, high-value added natural products, Raw materials and other sectors, Currently, there is bisabolol, 5
Twining Biology (301301.SZ): The synthetic biology project has now brought part of the company's revenue
Gelonghui, May 16, 丨 Chuan Ning Biotech (301301.SZ) said on the investor interactive platform that the company's synthetic biology project has brought some revenue to the company, but the current share of revenue is still relatively small. In the future, in the field of synthetic biology, the company will focus on health product raw materials, biological pesticides, high-value-added natural products, high-end cosmetic ingredients, etc., and the company will give full play to its existing advantages and continuously increase the contribution of synthetic biology products to the company's revenue.
Chuan Ning Biotech (301301.SZ): 2023 equity distribution, 10 distributions of 2.25 yuan, share registration date May 21
On May 15, Ge Longhui Biotech (301301.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 2.24,5595 (tax included) to all shareholders for every 10 shares based on the company's current total share capital of 2,227,160,000 shares. The share registration date for this equity distribution is May 21, 2024, and the ex-dividend date is May 22, 2024.
Chuan Ning Biology (301301.SZ): Currently not cooperating with Jiangnan University
Gelonghui, May 14, 丨 Channing Biology (301301.SZ) said on the investor interactive platform that the company has not yet cooperated with Jiangnan University. The company has set up a research institute in Shanghai, and also has cooperative projects with various biological research institutes and well-known universities such as the Institute of Microbiology of the Chinese Academy of Sciences, the Tianjin Institute of Industrial Biotechnology, and East China University of Technology.
Twining Biology (301301.SZ): Currently, some synthetic biology products are produced at the “synthetic biology production base”
Gelonghui, May 14, 丨 Chuan Ning Biology (301301.SZ) said on the investor interactive platform that the company currently produces some synthetic biology products at the “synthetic biology production base”, such as bisabolol, 5-hydroxytryptophan, etc.; at the same time, some products have already entered the small test and pilot phase, such as: squalane, ergothione, inositol, ecdoine, etc.; currently, the Shanghai Research Institute continues to step up research and development efforts to actively promote the delivery of new synthetic biology products.
No Data